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REVIEW
Abstract: Measurement of blood pressure in the clinic may provide a false impression of
blood pressure control. Ambulatory blood pressure monitoring (ABPM) allows the automatic
recording of the circadian variation in blood pressure and evaluation of the efficacy of
antihypertensive medication throughout the dosing interval. Ambulatory blood pressure
provides more effective prediction of cardiovascular risk; blood pressure control at the time
of heightened risk in the early morning after waking and before taking the next dose of
medication is becoming important in order to improve long-term prognosis. To achieve blood
pressure control in the early morning, a long-acting antihypertensive agent is essential.
Telmisartan, an angiotensin II receptor blocker, as well as having a terminal elimination half-
life of 24 h, has a large volume of distribution due to its high lipophilicity. The efficacy of
telmisartan 80 mg monotherapy has been demonstrated using ABPM, with superior reduction
in mean values for the last 6 h of the dosing interval compared with ramipril 10 mg and valsartan
80 mg. In addition, telmisartan 80 mg provides superior blood pressure control after a missed
dose compared with valsartan 160 mg. When combined with hydrochlorothiazide (HCTZ)
12.5 mg, telmisartan 40 mg and 80 mg is more effective than losartan/HCTZ (50/12.5 mg) at
the end of the dosing interval. Furthermore, greater reductions in last 6 h mean systolic blood
pressure (SBP) and diastolic blood pressure (DBP) are achieved with telmisartan/HCTZ (80/
12.5 mg) than with valsartan/HCTZ (160/12.5 mg) in obese patients with type 2 diabetes and
hypertension. Recent data from a large group of patients show that telmisartan 80 mg controls
the early morning blood pressure surge more effectively than ramipril 5–10 mg and, thus,
may have a greater beneficial effect on long-term cardiovascular risk. This supposition is
being tested in the ONgoing Telmisartan Alone and in combination with Ramipril Global
Endpoint Trial (ONTARGET) programme
Keywords: angiotensin II receptor blocker, antihypertensive, cardiovascular disease,
hypertension, morning, telmisartan
Introduction
Hypertension, which affects one in four adults worldwide (Kearney et al 2004), is an
important cause of cardiovascular morbidity and mortality, and antihypertensive
treatment is a common therapeutic intervention. Clinical guidelines have
recommended threshold levels for the implementation of antihypertensive therapy,
typically based on blood pressure levels assessed by the physician in an office
environment (Chobanian et al 2003; Guidelines Committee 2003; Whitworth 2003).
Increasingly, however, it is being recognized that such ‘in-clinic’ measurements do
not identify accurately variations in daily activity and their impact on blood pressure.
Such measurements can, therefore, miss true hypertension. Exact prevalence of so-
called ‘reversed white-coat hypertension’, ‘masked hypertension’, or ‘white-coat
normotension’ is difficult to establish, but four studies found incidences of between
9% and 23% (Pickering et al 2002). Masked hypertension carries an increased
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cardiovascular risk compared with the prognosis in
individuals with well-controlled home or ambulatory blood
pressure (Clement et al 2003; Bobrie et al 2004; Ohkubo et
al 2005; Pierdomenico et al 2005). In the elderly, the
cardiovascular risk in those with masked hypertension was
equal to that in those with sustained hypertension (Bjorklund
et al 2003).
The problem of masked hypertension can be exacerbated
in individuals receiving treatment for hypertension, because
many antihypertensive drugs have an effect at trough that
is substantially lower than their peak effect. Indeed, in the
1990s when most currently used antihypertensives were
evaluated, the US Food and Drug Administration’s criterion
for an effective antihypertensive agent was one with a
trough–peak ratio of no less than 50% (Meredith and Elliott
1994). A fair comparison among various antihypertensive
agents cannot be established solely on the basis of trough–
peak ratios (Lefebvre et al 2002). Since the medication is
usually administered once daily and taken in the morning
to encourage patient compliance, peak efficacy is likely to
occur around the time of morning blood pressure
measurement in the physician’s office. By contrast, the
trough effect may coincide with the early morning period
towards the end of the dosing interval. Consequently,
patients with treated hypertension often have relatively
higher morning blood pressure compared with office blood
pressure. An analysis of blood pressure control using
ambulatory blood pressure monitoring (ABPM) found that,
in 290 Spanish patients whose blood pressure was controlled
according to clinic measurements, only 38% displayed
control of morning blood pressure (Redon et al 2002).
In the evaluation of antihypertensive activity, ABPM is
regarded as preferable because ambulatory values are more
reproducible and established as more superior predictors of
cardiovascular risk than clinic measurements (Parati and
Lantelme 2002).
It has long been recognized that incidence of
cardiovascular events vary at different times of the day and
night; most strikingly, occurrences peak in the early morning
soon after waking (Muller et al 1985; Marler et al 1989;
Willich et al 1992; Elliott 1998). Analysis of data from
66 000 patients, for example, showed that myocardial
infarction was increased by 40% between 6.00 am and
midday (Cohen 1997). Hence, when prescribing an
antihypertensive agent, it is important that a long-acting
agent is given to ensure sustained control of blood pressure
at the time of heightened risk. The importance of 24 h blood
pressure control has been endorsed in the current European
Society of Hypertension/European Society of Cardiology
guidelines (Guidelines Committee 2003). The use of
noninvasive ABPM allows blood pressure to be measured
at regular pre-programmed intervals (usually every 15 or
20 minutes). Once the data are downloaded, circadian
variations in systolic blood pressure (SBP) and diastolic
blood pressure (DBP) can be analyzed and mean values for
specific periods (eg, 24 h, morning, daytime, night-time, and
last 6 h of the dosing interval) calculated.
Pharmacological properties of
telmisartan
Angiotensin II receptor blockers (ARBs) are highly effective
antihypertensive agents and are widely regarded as having
tolerability profiles similar to that of placebo (Meredith
2005). Of the commercially available ARBs, telmisartan has
the longest half-life of about 24 h (Burnier and Maillard
2001; Brunner 2002). This suggests that telmisartan should
have a long duration of action, thus ensuring blood pressure
control throughout the once-daily dosing interval. Another
feature distinguishing telmisartan from other ARBs is its
high lipophilicity (Wienen et al 2000). This enhances tissue
penetration, intracellular absorption and bioavailability. The
high lipophilicity is reflected in the high volume of
distribution of approximately 500 L (Stangier et al 2000).
The high lipophilicity of telmisartan, in comparison with
losartan, may confer vascular protection as has been
demonstrated in an animal model (Takai et al 2005). Another
feature that distinguishes telmisartan from the ARBs
candesartan cilexetil, losartan, and olmesartan is that it is
not a prodrug; thus antihypertensive potency is related to
the activity of the parent compound (Wienen et al 2000).
Efficacy of telmisartan in the early
morning hours
Monotherapy
The efficacy of telmisartan monotherapy has been
extensively studied using ABPM to establish whether the
long half-life translates into effective blood pressure control
at the end of the once-daily dosing interval. In addition to
double-blind studies, prospective, randomized open-label,
blinded-endpoint (PROBE) studies have been employed in
the evaluation of the duration of action of telmisartan.
Although in PROBE studies investigators are aware of the
treatment given, the automated and objective measurement
of blood pressure minimizes the potential for observer bias.
Meta-analysis has revealed that double-blind and PROBEVascular Health and Risk Management 2006:2(3) 197
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studies are statistically equivalent in terms of ruling out a
difference of ≥3 mm Hg in SBP and ≥2 mm Hg in DBP
(Smith et al 2003).
In a study comparing telmisartan 40–120 mg with the
long-acting calcium channel blocker amlopidine 5–10 mg,
both treatments produced comparable reductions in clinical
blood pressure after 12 weeks in patients with mild-to-
moderate hypertension (Lacourcière et al 1998). Clinic
measurements revealed that both telmisartan and amlodipine
reduced trough blood pressure, with no significant difference
between the two treatments. ABPM also showed that both
antihypertensive drugs reduced mean SBP and DBP at all
time periods compared with corresponding baseline values.
However, telmisartan brought about a significantly greater
reduction (p<0.05) in mean DBP during the night-time and
during the last 4 h of the dosing interval. There was also a
trend towards greater reduction of mean SBP with
telmisartan for these periods, although statistical significance
was not reached.
Telmisartan 80 mg displayed superior reduction in last
6 h mean SBP and DBP compared with ramipril 10 mg
after 14 weeks’ treatment in the Prospective Randomized
Investigation of the Safety and efficacy of Micardis
versus ramipril using ABPM (PRISMA) (Lacourcière,
Neutel, et al 2004; Lacouricière et al 2006; Williams et
al 2006). The two PROBE studies were identical in
design, one study being conducted in the US and Canada
(Lacourcière, Neutel, et al 2004; Lacouricière et al 2006)
and the other in Europe (Williams et al 2006). Ambulatory
blood pressure was recorded in a total of 634 patients
treated with telmisartan and 619 receiving ramipril. Mean
reductions in last 6 h mean SBP/DBP for telmisartan
80 mg were 12.0/8.4 mm Hg as opposed to 7.9/5.4 mm
Hg for ramipril 10 mg (p<0.0001 for both SBP and DBP)
(Williams et al 2005).
Compared with losartan 50 mg, telmisartan 40 mg or
80 mg demonstrated superior control of both SBP and DBP
during the last 6 h of the dosing interval (Mallion et al 1999).
The reductions in last 6 h mean SBP/DBP after 6 weeks’
treatment with losartan were 6.0/3.7 mm Hg for losartan,
whereas telmisartan 40 mg brought about reductions of 10.7/
6.8 mm Hg (p<0.05 for both SBP and DBP) and reductions
after telmisartan 80 mg treatment were 12.2/7.1 mm Hg
(p<0.05 for both SBP and DBP). A distinction between the
duration of action of telmisartan 10–40 mg and losartan 25–
100 mg was also noted in a Japanese study using home blood
pressure measurements performed soon after the patients
got up in the morning. The home morning DBP was
significantly lower in telmisartan-treated patients
(Nishimura et al 2005).
Another PROBE study comparing telmisartan 80 mg
with valsartan 80 mg after treatment for 8 weeks detected a
significantly greater reduction in the last 6 h mean DBP in
telmisartan-treated patients (7.5 mm Hg vs 5.2 mm Hg)
(Littlejohn et al 2000). The dose of valsartan used was that
recommended at the time. Subsequently, it was reported that
the antihypertensive efficacy of valsartan was enhanced if
the dose was increased to 160 mg (Verdecchia and Angeli
2004). This doubling of the dose did not, however,
compromise the placebo-like tolerability profile. More
recently, two identically designed multinational,
randomized, double-blind, forced-titration studies compared
telmisartan 40–80 mg with valsartan 80–160 mg
(Lacourcière, Krzesinski, et al 2004). After 4 weeks of high-
dose treatment, patients received either 1 day’s double-blind
active therapy or placebo (ie, a missed dose). Following a
further 2 weeks’ active treatment, a cross-over was
performed, such that patients who had previously received
1 day’s placebo received active therapy and vice versa.
Pooled data from 877 patients evaluated in the two studies
demonstrated that, after active therapy, the last 6 h mean
DBP was reduced by 7.6 mm Hg with telmisartan compared
with 5.8 mm Hg with valsartan (p=0.0044). Telmisartan also
proved superior to valsartan in reducing the last 6 h mean
SBP (adjusted mean reduction, 11.1 mm Hg vs 9.1 mm Hg,
respectively; p=0.0066). After a missed dose, the 24 h mean
DBP was reduced by 7.2 mm Hg with telmisartan compared
with 5.5 mm Hg with valsartan (p=0.0004). The reduction
in 24 h mean SBP after a missed dose was 10.7 mm Hg with
telmisartan and 8.7 mm Hg with valsartan (p=0.0024). It
was also observed in one of the two studies that there was a
notable trend for greater blood pressure reduction in the
telmisartan group compared with the valsartan group in latter
part of the dosing interval on the day on which a dose was
missed (White et al 2004). These data indicate that the longer
half-life of telmisartan (Stangier et al 2000) compared with
valsartan (Markham and Goa 1997) confers more sustained
blood control, especially at the end of the dosing period,
and preserves efficacy in poorly compliant patients in the
event of a missed dose.
To address the criticism that clinical trials in hypertension
may not provide a fair assessment of the effectiveness of
antihypertensive drugs in clinical practice, an ABPM study
was performed in the community (White et al 2005). The
Micardis
® Community Ambulatory Monitoring Trial
(MICCAT 2) evaluated telmisartan either alone or inVascular Health and Risk Management 2006:2(3) 198
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combination with low-dose hydrochlorothiazide (HCTZ)
12.5 mg in hypertensive patients who were untreated or
currently receiving antihypertensive medication.
Telmisartan-based treatment produced highly significant
reductions in the daytime and night-time mean blood
pressures. During the first 4 h after waking, telmisartan
reduced SBP/DBP by a mean of 11.5/7.0 mm Hg (p<0.0001
for both). In the long term, a 10 mm Hg lowering of SBP or
a 5 mm Hg lowering of DBP would be associated with an
approximately 40% lower risk of death from stroke and
about a 30% lower risk of death from ischemic heart disease
and other vascular causes (Lewington et al 2002).
In combination with HCTZ
In many patients, more than one antihypertensive drug may
be required to achieve effective blood pressure control. By
combining two different classes of antihypertensives, it may
be possible to provide complementary, additive, or
synergistic antihypertensive effects because of the drugs’
different mechanisms of action. The use of low doses of
two drugs may provide superior reduction of blood pressure
to higher doses of one drug and may enhance tolerability,
leading to improve compliance (Weir 1998). ARBs, by
targeting the renin–angiotensin system (RAS), modulate the
vasopressor activity of angiotensin II. In contrast, thiazide
diuretics reduce blood pressure mainly because of their
natriuretic mode of action (Motwani 2002). However, to
compensate for sodium depletion, the RAS is stimulated by
thiazide diuretics. Using an ARB offsets this stimulation
and, hence, further reduces blood pressure. In addition,
diuretic-induced potassium loss is redressed by co-
administering an ARB because of the attenuation of
angiotensin II-mediated aldosterone release. Clinical trials
have shown that the tolerability of ARB monotherapy is
maintained when the drug is combined with low-dose HCTZ
(Meredith 2005).
Two PROBE studies have evaluated the efficacy of two
fixed-dose telmisartan/HCTZ combinations (40/12.5 mg and
80/12.5 mg) versus a fixed-dose combination of losartan/
HCTZ (50/12.5 mg) (Lacourcière et al 2003; Neutel et al
2005). In the study by Lacourcière et al (2003), after
treatment for 6 weeks, losartan/HCTZ reduced last 6 h mean
SBP/DBP by 15.0/9.7 mm Hg. The lower-dose telmisartan/
HCTZ combination reduced last 6 h mean SBP/DBP by a
further 2.5/1.8 mmHg (p<0.05 for both). For the higher-dose
telmisartan/HCTZ combination, there was an additional
reduction in last 6h mean SBP/DBP of 3.4/2.5 mm Hg
(p<0.01 for both) compared with the losartan/HCTZ
combination. In the second study, also involving 6 weeks’
active treatment, both telmisartan/HCTZ fixed-dose
combinations produced significantly greater reductions in
the last 6 h mean DBP than losartan/HCTZ (50/12.5 mg).
The adjusted mean difference from the losartan combination
in favour of telmisartan/HCTZ 40/12.5 mg was –2.0 mm Hg
(p=0.0031) (Neutel et al 2005). Telmisartan/HCTZ 80/
12.5 mg also brought about significantly greater reductions
in the last 6 h mean DBP compared with the losartan/HCTZ
combination (adjusted mean difference –2.8 mm Hg;
p=0.0003), In the case of last 6 h mean SBP, the adjusted
mean   differences   compared   with   losartan/HCTZ   were
–2.6 mm Hg (p=0.0048) in favour of the lower-dose
telmisartan/HCTZ combination and –3.5 mm Hg (p=0.0018)
in favour of telmisartan/HCTZ 80/12.5 mg.
Achieving blood pressure control is important in patients
with metabolic syndrome because of the heightened risk of
target-organ damage (ADA 2002), leading to cardiovascular
and renal disease (Cuspidi et al 2004). Being overweight is
linked to hypertension (Heyden and Schneider 1990), and
it has been shown that RAS activity is heightened in adipose
tissue (Heyden and Schneider 1990; Rahmouni et al 2005).
In the Study of Micardis in Obese/Overweight Type 2
diabetics with Hypertension (SMOOTH), patients received
telmisartan 80 mg or valsartan 160 mg monotherapy for 4
weeks (Sharma et al 2005). Thereafter, HCTZ 12.5 mg was
also given in addition to all patients for 6 weeks. The last
6 h mean SBP/DBP were reduced in the telmisartan/HCTZ
group by 18.4/9.7 mm Hg and by 14.5/7.7 mm Hg in
valsartan/HCTZ-treated patients. This represented a
significant adjusted mean difference of –3.9 mm Hg
(p<0.0001) for SBP and –2.0 mm Hg (p=0.0007) for DBP
in favor of telmisartan/HCTZ.
In the elderly, systolic hypertension, in the absence of
significant diastolic hypertension, is highly prevalent and
is associated with an increased risk of cardiovascular death
(Basile 2002). It has also been found that a high morning
SBP surge in the elderly is significantly associated with the
risk of silent cerebral infarct and stroke (Kario et al 2003).
A force-titration PROBE study was performed in 638 elderly
patients with systolic hypertension to compare telmisartan/
HCTZ 80/12.5 mg with amlodipine/HCTZ 10/12.5 mg
(Neldam et al 2005). The reduction from baseline in adjusted
last 6 h mean SBP was 18.8 mm Hg for telmisartan/HCTZ
and 17.7 mm Hg for amlodipine/HCTZ. The difference in
favour of telmisartan/HCTZ of –1.1 mm Hg, confirms that
telmisartan/HCTZ was at least as effective as amlodipine/
HCTZ. The study also demonstrated that telmisartan/HCTZVascular Health and Risk Management 2006:2(3) 199
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produced a significantly greater reduction in 24 h mean
(p=0.0010), daytime (p=0.0002) and morning SBP
(p=0.0105) compared with amlodipine/HCTZ. In this
study, the incidence of drug-related adverse events
distinguished telmisartan-based therapy from that based
on amlodipine: 8.0% in the telmisartan group but 33.4%
amlodipine experienced one or more adverse events
(p<0.0001). This was largely attributable to peripheral
oedema, which was reported in 1.2% of telmisartan-group
patients, but in 24.3% (p<0.0001) of amlodipine-group
patients
Early morning blood pressure
surge
In general, hypertensive and normotensive individuals
exhibit a similar circadian variation in blood pressure, levels
being highest during the daytime and lowest in the middle
of the night (Staessen et al 1997). On awakening, the blood
pressure surges, but the extent of this surge can vary in
different individuals with some displaying morning
hypertension (Gosse et al 2004). In other subjects, blood
pressure is elevated at night and hypertension persists in
the morning. A direct correlation exists between SBP on
arising and left ventricular mass (Gosse et al 1997), and the
SBP on arising has been shown to be significantly higher in
the subjects who have cardiovascular complications (Gosse
et al 2001, 2004). Multivariate analysis found that the
association between early morning blood pressure and
cardiovascular risk was independent of age and 24 h blood
pressure. A relationship has also been demonstrated between
a high early morning blood pressure surge and
microalbuminuria (Polonia et al 2005).
In addition, a study conducted in elderly Japanese
subjects showed that the incidence of silent and overt
cerebrovascular lesions was highest in those with the greatest
morning blood pressure surge (Kario et al 2003). In that
study, an early morning blood pressure surge of ≥55 mm
Hg was associated with a 2.5-fold increase in overt stroke
and silent cerebral infarction. A recent meta-analysis has
shown that, in clinical trials in hypertensive or high-risk
patients, gradients in SBP accounted for most differences
in outcome (Staessen et al 2005).
The PRISMA studies were novel in the fact that the time
of waking was recorded for each patient (Lacourcière,
Neutel, et al 2004; Lacouricière et al 2006; Williams et al
2006). The early morning blood pressure surge was
determined as the difference between night-time low (mean
of all measurements within a ±30-minute interval around
the minimum blood pressure during sleeping) and early
morning mean (mean during the 2 h after wakening) (Figure
1) (Eguchi et al 2003). Telmisartan 80 mg proved
significantly superior to ramipril 10 mg in the reducing night-
time low and early morning mean SBP and DBP (p<0.0001
for all) compared with baseline values (Gosse et al 2005).
Telmisartan reduced the overall mean systolic surge by
1.5 mm Hg, whereas ramipril caused an increase of 0.3 mm
Hg (p=0.0049). The magnitude of surge reduction was
greatest in the quartile with highest baseline early morning
SBP surge: telmisartan –12.7 mm Hg, ramipril –7.8 mm Hg
(p=0.0004). Telmisartan also reduced the surge compared
with ramipril in dippers, but there were no differences
between the two groups in non-dippers.
Further evidence of telmisartan controlling the early
morning blood pressure surge comes from the MICCAT 2
study (White et al 2005).  Among the 1628 patients enrolled,
95 had a SBP surge of >30 mm Hg after waking. In these
patients, the 4 h post-waking mean SBP/DBP fell by an
average of 15.0/8.5 mm Hg with telmisartan monotherapy
and by 19.4/11.6 mm Hg with combination therapy.
Conclusions
Elevated blood pressure in the early morning is associated
with increased cardiovascular risk. It is crucial that
antihypertensive medication controls blood pressure to
minimize this risk at this time. Unfortunately some
Figure 1 Circadian pattern of blood pressure showing night-time low (NTL),
time of waking, and early morning mean (EMM) for systolic blood pressure
(SBP) and diastolic blood pressure (DBP).Vascular Health and Risk Management 2006:2(3) 200
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antihypertensives given once daily in the morning may not
fulfil this requirement and may place the patient at increased
risk. The ARB with the longest half-life is telmisartan. Its
potential to reduce blood pressure in the risky early morning
hours has been demonstrated in numerous clinical studies
using ABPM. Also, of particular importance is the fact that
telmisartan has been shown to reduce the early morning
blood pressure surge.
The cardiovascular relevance of these observations is
being tested in the ONgoing Telmisartan Alone and in
combination with Ramipril Global Endpoint Trial
(ONTARGET) programme (Teo et al 2004). Currently, there
is uncertainty about the role of ARBs when used alone or in
combination with an ACE inhibitor in high-risk populations
with controlled hypertension. The primary objectives of
ONTARGET are to determine if the combination of the ARB
telmisartan and the ACE inhibitor ramipril is more effective
than ramipril alone, and if telmisartan is at least as effective
as ramipril. The sister study is Telmisartan Randomized
AssessmeNt Study in aCE iNtolerant subjects with
cardiovascular Disease (TRANSCEND), which has been
designed to establish whether or not telmisartan is superior
to placebo in patients who are intolerant of ACE inhibitors.
The primary outcome for both trials is the composite of
cardiovascular death, myocardial infarction, stroke, or
hospitalization for heart failure.
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